Charles Schubert, MD
Vascular Surgery · Elmwood Park, ILNPI 1245219641
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,511 of the $8,224 with a category attached, or 67.0%. 35 manufacturers reported payments, led by Penumbra, Inc. at 32.6% of the total. Reporting peaked in 2024 at $2,818 and has fallen 81.5% since, to $520 in 2025.
Across 141 payments — averaging $58.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$3K
- Terumo Medical Corporation$1K
- Lemaitre Vascular, Inc.$665
- Medtronic$659
- Smith+Nephew$601
- Bard Peripheral Vascular, Inc.$493
- plus $2K from 29 others
What the payments were for
- Travel & lodging$2,68233%
- Food & beverage$5,51167%
- Education$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 10 | $2,682 |
| Terumo Medical Corporation | 8 | $1,012 |
| Lemaitre Vascular, Inc. | 10 | $665 |
| Medtronic(2 entities) | 14 | $659 |
| Smith+Nephew | 25 | $601 |
| Bard Peripheral Vascular, Inc. | 4 | $493 |
| Johnson & Johnson(2 entities) | 16 | $319 |
| Integra Lifesciences Corporation | 5 | $307 |
| W. L. Gore & Associates, Inc. | 5 | $177 |
| Intuitive Surgical | 2 | $154 |
| Organogenesis Inc. | 6 | $133 |
| Kerecis Limited | 3 | $131 |
| Mimedx Group, Inc. | 1 | $127 |
| Acera Surgical, Inc. | 3 | $99 |
| Shockwave Medical, Inc | 3 | $98 |
| Tactile Systems Technology Inc | 4 | $74 |
| Osiris Therapeutics Inc. | 3 | $73 |
| Cardiovascular Systems Inc. | 2 | $51 |
| Covidien LP | 1 | $38 |
| Philips North America LLC | 1 | $29 |
| BD | 1 | $28 |
| Misonix Inc | 1 | $25 |
| TELA Bio, Inc. | 1 | $25 |
| Vertex | 1 | $24 |
| Pacira Pharmaceuticals Incorporated | 1 | $23 |
| Avinger Inc. | 1 | $22 |
| Aroa Biosurgery Incorporated | 1 | $21 |
| Cook Medical LLC | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Biocompatibles, Inc. | 1 | $20 |
| Myriad Genetic Laboratories, Inc. | 1 | $20 |
| Innocoll Pharmaceuticals Limited | 1 | $17 |
| KCI USA, Inc. | 1 | $13 |
| Angiodynamics, Inc. | 1 | $12 |
| Innovation Technologies Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$2,393
- Navicross$653
- Glidesheath$653
- GlideWire$653
- INTEGRA$500
- VALVULOTOM$249
- ARTEGRAFT VASCULAR GRAFT$243
- INTEGRA DERMAL REGENERATION TEMPLATE$167
- PRIMATRIX$167
- Indigo$159
- Abre$157
- Penumbra System$112
- GrafixPL$111
- Stravix$111
- Sonicision$109
- WAVELINQ$102
How this compares
$8,224 in reported general payments places this provider in the 65th percentile of 170 vascular surgery providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 74 | $60,298 |
| Cilostazol | 28 | $810 |
| ClopidogrelClopidogrel Bisulfate | 35 | $553 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 32 | $198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $319 | $60,29874 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 170 vascular surgery providers in Illinois.
Other vascular surgery in Elmwood Park
- Ross MilnerChicago$1.3M
- Sapan DesaiArlington Heights$1.2M
- Nabeel RanaPeoria$934K
- Atif BaqaiPark Ridge$567K
- Trissa BabrowskiChicago$292K
- Tejas ShahDowners Grove$213K
- Carlos BecharaMaywood$199K
- Dhiren PatelSpringfield$121K
- Heron RodriguezChicago$105K
- Michael SoultMaywood$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.